Caspofungin: first approved agent in a new class of antifungals

Bibliography

• Merck & Co. Inc. Cancidas (Injectable formulation) package insert. Merck & Co. Inc.,Whitehouse Station, NJ, USA (2001).
   Google Scholar
• VAN DUIN D, CASADEVALL A, NOSANCHUK JD: Melanization of Cryptococcus neoformans and Histoplasma capsulatum reduces their susceptibilities to amphotericin B and caspofungin. Aritimicrob. Agents Chemother (2002) 46(11):3394–3400.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH: Update on antifungals targeted to the cell wall: focus on fi-1,3-glucan synthase inhibitors. Expert Opiri. Irivestig. Drugs (2001) 10 (2):269–280.
   PubMed Web of Science ®Google Scholar
• POWLES MA, LIBERATOR P, ANDERSON J et al: Efficacy of MK-991 (L-743,872), a semisynthetic pneumocandin, in murine models of Pneumocystis carinii. Aritimicrob. Agents Chemother. (1998) 42(8):1985–1989.
   PubMed Web of Science ®Google Scholar
• GEORGOPAPADAKOU NH, TKACZ JS: The fungal cell wall as a drug target. Trends Nlicrobia. (1995) 3(3):98–104.
   PubMedGoogle Scholar
• KURTZ MB, DOUGLAS CM: Lipopeptide inhibitors of fungal glucan synthase. I Med. Vet. Mycol. (1997) 35(2):79–86.
   PubMedGoogle Scholar
• FELDMESSER M, KRESS Y, MEDNICK A, CASADEVALL A: The effect of the echinocandin analogue caspofungin on cell wall glucan synthesis by Cryptococcus neoformans. ?Infect. Dis. (2000) 182(6):1791–1795.
   PubMed Web of Science ®Google Scholar
• JAMES PG, CHERNIAK R, JONES RG, STORTZ CA, REISS E: Cell wall glucans of Cryptococcus neoformans Cap 67. Carbohydr. Res. (1990) 198(1):23–38.
   PubMed Web of Science ®Google Scholar
• THOMPSON JR, DOUGLAS CM, LI W et al: A glucan synthase FKS1 homolog in Cryptococcus neoformans is single copy and encodes an essential function. ?Bacteria (1999) 181(2):444–453.
   PubMed Web of Science ®Google Scholar
• OSHEROV N, MAY GS, ALBERT ND, KONTOYIANNIS DP: Overexpression of Sbe2p, a Golgi protein, results in resistance to caspofungin in Saccharomyces cerevisiae. Aritimicrob. Agents Chemother. (2002) 46(8):2462–2469.
   PubMed Web of Science ®Google Scholar
• KURTZ MB, ABRUZZO G, FLATTERY A et al: Characterization of echinocandin-resistant mutants of Candida albicans: genetic, biochemical, and virulence studies. Infect. Immum (1996) 64(8):3244–3251.
   PubMed Web of Science ®Google Scholar
• WALDREP TW, KEISER P, WARE A et al.: Failure of intermittent caspofungin therapy to treat fluconazole-resistant mucocutaneous Candida despite apparent in vitro susceptibility. In: Program and Abstracts of the 42m Interscierice Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002) M–891.
   Google Scholar
• ••Report of four cases of fluconazole-resistant esophageal candidiasis that initially responded to intermittent therapy with caspofungin but then relapsed with more severe disease, in the absence of high-level caspofungin resistance.
   Google Scholar
• MORA-DUARTE J, BETTS R, ROTSTEIN C et al: Comparison of caspofungin and amphotericin B for invasive candidiasis. N Engl. I Med. (2002) 347(25):2020–2029.
   PubMed Web of Science ®Google Scholar
• ••A randomised, double-blind studycomparing caspofungin with amphotericin B as treatment of invasive candidiasis in 224 patients. This study indicated that the efficacy of caspofungin was similar to amphotericin B with reduced nephrotmdcity and infusion-related adverse events.
   Google Scholar
• BARTIZAL K, MOTYL M, HICKS P et al.: In vitro susceptibility results and correlation with outcome: results from the randomized invasive candidiasis study of caspofungin versus amphotericin B. In: Program am Abstracts of the 42ri Interscierice 820Expert Op/n. Pharmacother. (2003) 4(5) Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M–1240.
   Google Scholar
• HAJDU R, THOMPSON R, SUNDELOF JG et al.: Preliminary animal pharmacokinetics of the parenteral antifungal agent MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2339–2344.
   PubMed Web of Science ®Google Scholar
• PETRAITIS V, PETRAITIENE R, KELAHER A et al: Antifungal activity and safety of caspofungin against experimental disseminated candidiasis in persistently neutropenic rabbits. In: Program and Abstracts of the 42ri Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA (2002) M–188.
   Google Scholar
• •Demonstrated concentration-dependent killing effects of caspofungin in disseminated C. albicans and C. glabrata infection in persistently neutropenic rabbits.
   Google Scholar
• STONE JA, HOLLAND SD, WICKERSHAM PJ et al: Single- and multiple-dose pharmacokinetics of caspofungin in healthy men. Antimicrob. Agents Chemother. (2002) 46(3):739–745.
   PubMed Web of Science ®Google Scholar
• BALANI SK, XU X, ARISON BH et al: Metabolites of caspofungin acetate, a potent antifungal agent, in human plasma and urine. Drug Metab. Dispos. (2000) 28(11):1274–1278.
   PubMed Web of Science ®Google Scholar
• STONE JA, HOLLAND SD, LI S et al: Effect of hepatic insufficiency on the pharmacokinetics of caspofungin. In: Program and Abstracts of the 4Ist Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA (2001) A–14.
   Google Scholar
• STONE JA, BALLOW CH, HOLLAND SD et al.: Single dose caspofungin pharmacokinetics in healthy elderly subjects. In: Program and Abstracts of the 4gh Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (2000) 853.
   Google Scholar
• STONE JA, MCCREA JB, WICKERSHAM PJ et al: A Phase I study of caspofungin evaluating the potential for drug interactions with itraconazole, the effect of gender, and the use of a loading dose regimen. In: Program and Abstracts of the 4gh Interscience Conference on Antimicrobial Agents and Chemotherapy Toronto, Ontario, Canada (2000) 854.
   Google Scholar
• WALSH TJ, ADAMSON PC, SEIBEL NL et al.: Pharmacokinetics of caspofungin in pediatric patients. In: Program and Abstracts of the 42m Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M–896.
   Google Scholar
• ••Describes pharmacokinetics ofcaspofungin in nine paediatric patients with haematological malignancies and indicates that doses of caspofungin 50 mg/m2/day might approximate caspofungin serum concentrations of adults receiving 50 mg/day i.v.
   Google Scholar
• STONE JA, HOLLAND SD, WICKERSHAM PJ et al: Drug interactions between caspofungin and tacrolimus. In: Program and Abstracts of the 41st Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA (2001) A–13.
   Google Scholar
• ARATHOON EG, GOTUZZO E, NORIEGA LM et al: Randomized, double-blind, multicenter study of caspofungin versus amphotericin B for treatment of oropharyngeal and esophageal candidiases. Antimicrob. Agents Chemother. (2002) 46(2):451–457.
   PubMed Web of Science ®Google Scholar
• ••A Phase II, randomised, double-blind,dose-ranging study demonstrated that caspofungin was as efficacious as amphotericin B in the treatment of oropharyngeal and esophageal candidiasis.
   Google Scholar
• VILLANUEVA A, ARATHOON EG, GOTUZZO E et al.: A randomized double-blind study of caspofungin versus amphotericin for the treatment of candidal esophagitis. Chit. Infect. Dis. (2001) 33 (9):1529–1535.
   PubMed Web of Science ®Google Scholar
• ••A Phase II, randomised, double-blind,dose-ranging study demonstrated that caspofungin was as efficacious as amphotericin B in the treatment of esophageal candidiasis.
   Google Scholar
• BARTIZAL K, GILL CJ, ABRUZZO GK et al.: In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872). Antimicrob. Agents Chemother. (1997) 41(11):2326–2332.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, KLEPSER ME, ERNST ME, MESSER SA, PFALLER MA: In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods. Diag. Microbial Infect. Dis. (1999) 33 (2):75–80.
   PubMed Web of Science ®Google Scholar
• ABRUZZO GK, FLATTERY AM, GILL CJ et al.: Evaluation of the echinocandin antifungal MK-0991 (L-743,872): efficacies in mouse models of disseminated aspergillosis, candidiasis, and cryptococcosis. Antimicrob. Agents Chemother. (1997) 41(11):2333–2338.
   PubMed Web of Science ®Google Scholar
• ABRUZZO GK, GILL CJ, FLATTERY AM et al.: Efficacy of the echinocandin caspofungin against disseminated aspergillosis and candidiasis in cyclophosphamide-induced immunosuppressed mice. Antimicrob. Agents Chemother. (2000) 44(9):2310–2318.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR LK, LUTHER MF, FOTHERGILL AW: Treatment of murine disseminated candidiasis with L-743,872. Antimicrob. Agents Chemother. (1997) 41(8):1775–1777.
   PubMed Web of Science ®Google Scholar
• PETRAITIENE R, PETRAITIS V, GROLL AH et al: Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia. Antimicrob. Agents Chemother. (2002) 46(1):12–23.
   PubMed Web of Science ®Google Scholar
• ERNST EJ, KLEPSER ME, PFALLER MA: Postantifungal effects of echinocandin, azole, and polyene antifungal agents against Candida albicans and Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44(4):1108–1111.
   PubMed Web of Science ®Google Scholar
• GEISS HK and DILGER S: The post-antifungal effect (PAPE) of caspofungin. In: Program and Abstracts of the 42'd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002):A–495.
   Google Scholar
• RAMESH MS, BASKARAN I, GANESAN LT, MANAVATHU EK, CHANDRASEKAR PH: Postantifungal effect of older and newer antifungal agents on Aspergillus fumigatus and Candida albicans. In: Program and Abstracts of the 42ri Interscience Conference on Antimicrobial Agents and Chemotherapy Chicago, IL, USA (2001) J–105.
   Google Scholar
• RAMAGE G, VANDEWALLE K, BACHMANN SP, WICKES BL, LOPEZ-RIBOT JL: In vitro pharmacodynamic properties of three antifungal agents against preformed Candida albicans biofilms determined by time-kill studies. In: Program and Abstracts of the 42m Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002):M-468. 821
   Google Scholar
• BACHMANN SP, VANDEWALLE K, RAMAGE G et al: In vitro Interactions between caspofungin and Candida albicans biofilms. In: P rogram arid Abstracts of the 42'd Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA (2002):M–1512.
   Google Scholar
• KUHN DM, GEORGE T, CHANDRA J, MUKHERJEE PK, GHANNOUM MA: Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins. Antimicrob. Agents Chemother. (2002) 46(6):1773–1780.
   PubMed Web of Science ®Google Scholar
• •An in vitro study demonstrating that caspofungin, micafungin, and lipid amphotericin B formulations had activity against bio-film producing Candida spp. whereas newer triazoles did not.
   Google Scholar
• KRISHNARAO TV, GALGIANI JN: Comparison of the in vitro activities of the echinocandin LY303366, the pneumocandin MK-0991, and fluconazole against Candida species and Cryptococcus neoformans. Antimicrob. Agents Chemother. (1997) 41(9):1957–1960.
   PubMed Web of Science ®Google Scholar
• FRANZOT SP, CASADEVALL A: Pneumocandin L-743,872 enhances the activities of amphotericin B and fluconazole against Cryptococcus neoformans in vitro. Antimicrob. Agents Chemother. (1997) 41(2):331–336.
   PubMed Web of Science ®Google Scholar
• DEL POETA M, CRUZ MC, CARDENAS ME, PERFECT JR, HEITMAN J: Synergistic antifungal activities of bafilomycin A(1), fluconazole, and the pneumocandin MK-0991/ caspofungin acetate (L-743,873) with calcineurin inhibitors FK506 and L-685,818 against Cryptococcus neoformans. Antimicrob. Agents Chemother. (2000) 44(3):739–746.
   PubMed Web of Science ®Google Scholar
• NELSON PW, LOZANO-CHIU M, REX JH: In vitro growth-inhibitory activity of pneumocandins L-733,560 and L-743,872 against putatively amphotericin B- and fluconazole-resistant Candida spp. isolates: influence of assay conditions. Med. Vet. Myra]. (1997) 35(4):285–287.
   Google Scholar
• Reference method for broth dilution antifungal susceptibility testing of yeasts, approved standard. NCCLS document M27A. National Committee for Clinical Laboratory Standards,Wayne, PA, USA (1997).
   Google Scholar
• PFALLER MA, MESSER SA, MILLS K, BOLMSTROM A, JONES RN: Evaluation of E-test method for determining caspofungin (MK-0991) susceptibilities of 726 clinical isolates of Candida species. j Clin. Microbial. (2001) 39(12):4387–4389.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, JONES RN, DOERN GV et al: International surveillance of blood stream infections due to Candida species in the European SENTRY program: species distribution and antifungal susceptibility including the investigational triazole and echinocandin agents. SENTRY participant group (Europe). Diag. Microbial. Infect. Dis. (1999) 35(1):19–25.
   PubMed Web of Science ®Google Scholar
• MARCO E PFALLER MA, MESSER SA, JONES RN: Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp. Diag. Microbial Infect. Dis. (1998) 32(1):33–37.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MESSER SA, GEE S et al: In vitro susceptibilities of Candida spp. dubliniensis isolates tested against the new triazole and echinocandin antifungal agents. I CBI]. Microbial (1999) 37(3):870–872.
   Google Scholar
• BARCHIESI E SCHIMIZZI AM, FOTHERGILL AW, SCALISE G, RINALDI MG: In vitro activity of the new echinocandin antifungal, MK-0991, against common and uncommon clinical isolates of Candida species. Eur. j CBI]. Microbial Infect. Dis. (1999) 18(4):302–304.
   PubMed Web of Science ®Google Scholar
• ESPINEL-INGROFF A: Comparison of in vitro activities of the new triazole 5CH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts. CBI]. Microbial (1998) 36(10):2950–2956.
   PubMed Web of Science ®Google Scholar
• GONZALEZ GM, TIJERINA R, NAJVAR LK et al.: Correlation between antifungal susceptibilities of Coccidioides immitis in vitro and antifungal treatment with caspofungin in a mouse model. Antimicrob. Agents Chemother. (2001) 45(6):1854–1859.
   PubMed Web of Science ®Google Scholar
• ZAAS AK, BOYCE M, SCHELL W, ALEXANDER LODGE BD, PERFECT JR: Rhodotorula fungemia: clinical outcomes and in vitro antifungal susceptibilities. In: Program arid Abstracts of the 42'd Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002):M–900.
   Google Scholar
• Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, approved standard. NCCLS document M-38A. National Committee for Clinical Laboratory Standards,Wayne, PA, USA (2002).
   Google Scholar
• HAWSER SP, JESSUP C, VITULLO J, GHANNOUM MA: Utility of 2,3-bis (2-methoxy-4-nitro-5-sulfopheny1)-5-Rphenyl-amino)carbony11-2H-tetrazolium hydroxide (XTT) and minimum effective concentration assays in the determination of antifungal susceptibility of Aspergillus fumigatus to the lipopeptide class compounds. j Chia. Microbial (2001) 39(7):2738–2741.
   Web of Science ®Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates. Antimicrob. Agents Chemother. (2001) 45(1):327–330.
   PubMed Web of Science ®Google Scholar
• BEAU VAIS A, BRUNEAU JM, MOL PC et al.: Glucan synthase complex of Aspergillus fumigatus. j Bacterial (2001) 183(7):2273–2279.
   PubMed Web of Science ®Google Scholar
• BOWMAN JC, HICKS PS, KURTZ MB et al.: The antifungal echinocandin caspofungin acetate kills growing cells of Aspergillus fumigatus in vitro. Antimicrob. Agents Chemother. (2002) 46(9):3001–3012.
   PubMed Web of Science ®Google Scholar
• DEL POETA M, SCHELL WA, PERFECT JR: In vitro antifungal activity of pneumocandin L-743,872 against a variety of clinically important molds. Antimicrob. Agents Chemother. (1997) 41(8):1835–1836.
   PubMed Web of Science ®Google Scholar
• PFALLER MA, MARCO E MESSER SA, JONES RN: In vitro activity of two echinocandin derivatives, LY303366 and MK-0991 (L-743,792), against clinical isolates of Aspergillus, Fusarium, Rhizopus, and other filamentous fungi. Diag. 11/licrobial. Infect. Dis. (1998) 30(4):251–255.
   Google Scholar
• ARIKAN S, LOZANO-CHIU M, PAETZNICK V, REX JH: In vitro synergy of caspofungin and amphotericin B against Aspergillus and Fusarium spp. Antimicrob. Agents Chemother. (2002) 46(1):245–247.
   PubMed Web of Science ®Google Scholar
• PEREA S, GONZALEZ G, FOTHERGILL AW et al.: In vitro interaction of caspofungin acetate with voriconazole against clinical isolates of Aspergillus spp. Antimicrob. Agents Chemother. (2002) 46(9):3039–3041.
   PubMed Web of Science ®Google Scholar
• LIU W, LEWIS RE, MAY GS, KONTOYIANNIS DP: Pre-exposure of A. fumigatus to fluconazole induces tolerance to itraconazole in vitro. In: Program arid Abstracts of the 42m Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M–852.
   Google Scholar
• GRAYBILL JR, BOCANEGRA R, LUTHER M, FOTHERGILL A, RINALDI MJ: Treatment of murine Candida krusei or Candida glabrata infection with L-743,872. Antimicrob. Agents Chemother. (1997) 41(9):1937–1939.
   PubMed Web of Science ®Google Scholar
• JU JY, POLHAMUS C, MARR KA, HOLLAND SM, BENNETT JE: Efficacies of fluconazole, caspofungin, and amphotericin B in Candida glabrata-infected p47phox-/-knockout mice. Antimicrob. Agents Chemother. (2002) 46(5):1240–1245.
   PubMed Web of Science ®Google Scholar
• GRAYBILL JR, NAJVAR LK, MONTALBO EM et al.: Treatment of histoplasmosis with MK-991 (L-743,872). Antimicrob. Agents Chemother. (1998) 42(1):151–153.
   PubMed Web of Science ®Google Scholar
• KOHLER S, WHEAT LJ, CONNOLLY P et al.: Comparison of the echinocandin caspofungin with amphotericin B for treatment of histoplasmosis following pulmonary challenge in a murine model. Antimicrob. Agents Chemother. (2000) 44(7):1850–1854.
   PubMed Web of Science ®Google Scholar
• BOWMAN JC, ABRUZZO GK, ANDERSON JW etal.: Quantitative PCR assay to measure Aspergillus fumigatus burden in a murine model of disseminated aspergillosis: demonstration of efficacy of caspofungin acetate. Antimicrob. Agents Chemother. (2001) 45(12):3474–3481.
   Google Scholar
• KIRKPATRICK WR, PEREA S, COCO BJ, PATTERSON TF: Efficacy of caspofungin alone and in combination with voriconazole in a guinea pig model of invasive aspergillosis. Antimicrob. Agents Chemother. (2002) 46(8):2564–2568.
   PubMed Web of Science ®Google Scholar
• ••A study that demonstrates increasedefficacy of a combination of caspofungin and voriconazole against Aspergillus fumigatus in an animal model of transiently neutropenic, immunosuppressed guinea pigs.
   Google Scholar
• VILLANUEVA A, GOTUZZO E, ARATHOON EG etal.: A randomized double-blind study of caspofungin versus fluconazole for the treatment of esophageal candidiasis. Am. j Med. (2002) 113(4):294–299.
   Google Scholar
• ••Describes a Phase III, randomised trial inwhich caspofungin was as efficacious as fluconazole for the treatment of esophageal candidiasis.
   Google Scholar
• KARTSONIS N, DINUBILE MJ, BARTIZAL K et al: Efficacy of caspofungin in the treatment of esophageal candidiasis resistant to fluconazole. Acquir: Immune Defic. Syndr. (2002) 31(2):183–187.
   PubMed Web of Science ®Google Scholar
• MORA-DUARTE J, BETTS R, ROTSTEIN C et al: Caspofungin versus amphotericin B deoxycholate in the treatment of invasive candidiasis in neutropenic and non-neutropenic patients: a multi-centre, randomized, double-blind study. In: Program and Abstracts of the I Zb European Congress of Clinical Microbiology and Infectious Diseases, Milan, Italy (2002)0237.
   Google Scholar
• MAERTENS J, RAAD I, PETRIKKOS G et al.: Update of the multicenter noncomparative study of caspofungin in adults with invasive aspergillosis refractory or intolerant to other antifungal agents: analysis of 90 patients. In: Program and Abstracts of the 42m Interscience Conference on Antimicrobial Agents and Chemotherapy, San Diego, CA, USA (2002) M–868.
   Google Scholar
• ••Describes outcomes of 83 patients whoreceived 1 dose of caspofungin in a study of invasive aspergillosis infection among patients who were refractory or intolerant to other antifungal therapies.
   Google Scholar
• KOSS T, BAGHERI B, ZEANA C, ROMAGNOLI MF, GROSSMAN ME: Amphotericin B-resistant Aspergillus flavus infection successfully treated with caspofungin, a novel antifungal agent. Amer. Acad. Dermatol (2002) 46(6):945–947.
   PubMed Web of Science ®Google Scholar
• RUBIN MA, CARROLL KC, CAHILL BC: Caspofungin in combination with itraconazole for the treatment of invasive aspergillosis in humans. Clin Infect. Dis. (2002) 34(8):1160–1161.
   PubMed Web of Science ®Google Scholar
• •Two case reports of successful therapy with a combination of caspofungin and itraconazole for invasive Aspergillosis.
   Google Scholar
• ALIFF TB, MASLAK PG, JURCIC JG et al.: Refractory aspergillus pneumonia in patients with acute leukemia: successful therapy with combination caspofungin and liposomal amphotericin B. In: Program and Abstracts of the 4.7d Annual Meeting of the American Society of Hematology Orlando, FL, USA (2001):1381.
   Google Scholar
• KONTOYIANNIS DP, HACHEM R, LEWIS RE et al.: Efficacy and toxicity of the caspofungin/liposomal amphotericin B combination in documented or possible invasive aspergillosis in patients with hematologic malignancies. In: Program and Abstracts of the 42m Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002):M–1820.
   Google Scholar
• •Case series describing outcomes among 50 patients with invasive aspergillosis who received combination therapy with caspofungin and liposomal amphotericin B.
   Google Scholar
• SAFDAR A: Progressive cutaneous hyalohyphomycosis due to Paecilomyces lilacinus: rapid response to treatment with caspofungin and itraconazole. Clin. Infect. Dis. (2002) 34(10):1415–1417.
   PubMed Web of Science ®Google Scholar
• GOODMAN D, PAMER E, JAKUBOWSKI A, MORRIS C, SEPKOWITZ K: Breakthrough trichosporonosis in a bone marrow transplant recipient receiving caspofungin acetate. Clin Infect. Dis. (2002) 35(3):E35–E36.
   Web of Science ®Google Scholar
• STONE JA, MIGOYA E, LI S et al: Safety and pharmacokinetics of higher doses of caspofungin. In: Program and Abstracts of the 42m Interscience Conference on Antimicrobial Agents and Chemotherapy San Diego, CA, USA (2002):A–1319.
   Google Scholar
• •Describes safety of caspofungin at single doses of up to 210 mg in healthy volunteers.
   Google Scholar